Cisplatin/epinephrine injectable gel - Novartis

Drug Profile

Cisplatin/epinephrine injectable gel - Novartis

Alternative Names: CDDP TI; Cisplatin therapeutic implant; cisplatin-e therapeutic implant; IntraDose-CDDP™; MPI-5010

Latest Information Update: 03 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Matrix Pharmaceutical
  • Developer Novartis
  • Class Antineoplastics; Catecholamines; Ethanolamines; Platinum complexes
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Head and neck cancer
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer; Cancer metastases; Head and neck cancer; Liver cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Sarcoma; Solid tumours

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 15 May 2003 A study has been added to the Cancer therapeutic trials section
  • 13 Dec 2002 A study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top